Dexamethasone + Rituximab + Cyclophosphamide (DRC) × 6 cycles

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-DEXAMETHASONE` `DRUG-RITUXIMAB` `DRUG-CYCLOPHOSPHAMIDE`

ID	`REG-DRC-WM`
Type	Regimen
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	None declared
Sources	`SRC-NCCN-BCELL-2025`

Notes

Time-limited (6 months) chemoimmuno for WM — preferred when BTKi not accessible OR for CXCR4-WHIM-mutated WM (BTKi response weaker). IgM flare with rituximab can worsen hyperviscosity — plasmapheresis first if symptomatic.

Used By

Indication

IND-WM-1L-DRC - IND-WM-1L-DRC